XORTX Therapeutics Files 6-K Report
Ticker: XRTX · Form: 6-K · Filed: Sep 13, 2024 · CIK: 1729214
Sentiment: neutral
Topics: sec-filing, 6-k, reporting-status
TL;DR
XORTX files 6-K, confirms 20-F reporting, CEO signed off.
AI Summary
XORTX Therapeutics Inc. filed a Form 6-K on September 13, 2024. The report indicates the company is a foreign private issuer and will file its annual reports under Form 20-F. The filing was signed by CEO Allen Davidoff.
Why It Matters
This filing confirms XORTX Therapeutics Inc.'s status as a foreign private issuer and its reporting obligations with the SEC.
Risk Assessment
Risk Level: low — This is a routine administrative filing confirming reporting status and not disclosing new material financial or operational information.
Key Players & Entities
- XORTX Therapeutics Inc. (company) — Registrant
- Allen Davidoff (person) — Chief Executive Officer
- September 13, 2024 (date) — Filing Date
- Form 20-F (document) — Annual Report Filing
- Form 6-K (document) — Filing Type
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, for the month of September 2024.
Which annual report form will XORTX Therapeutics Inc. file?
XORTX Therapeutics Inc. indicates it files or will file annual reports under cover of Form 20-F.
Who signed this report on behalf of XORTX Therapeutics Inc.?
The report was signed by Allen Davidoff, Chief Executive Officer.
What is the filing date of this report?
The report was filed on September 13, 2024.
What is the Commission File Number for XORTX Therapeutics Inc.?
The Commission File Number for XORTX Therapeutics Inc. is 001-40858.
Filing Stats: 139 words · 1 min read · ~1 pages · Grade level 10.7 · Accepted 2024-09-13 07:00:08
Filing Documents
- f6k_091324.htm (6-K) — 4KB
- exh_991.htm (EX-99.1) — 7KB
- 0001171843-24-005176.txt ( ) — 12KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001-40858 XORTX Therapeutics Inc. 3710 – 33rd Street NW, Calgary, Alberta, T2L 2M1 Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F [ X ] Form 40-F [ ] SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. XORTX Therapeutics Inc. (Registrant) Date: September 13, 2024 By: /s/ Allen Davidoff Name: Allen Davidoff Title: Chief Executive Officer EXHIBIT INDEX 99.1 News release dated September 13, 2024